Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

2(50.0%)

N/A

1(25.0%)

Phase 2

1(25.0%)

4Total

Phase 3(2)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07536763Phase 3Not Yet Recruiting

Arterial Vascular Effects of Estetrol-drospirenone Combined Oral Contraceptive Pill

Role: collaborator

NCT06727734Phase 3Not Yet Recruiting

Levonorgestrel-piroxicam Versus Ulipristal Acetate for Emergency Contraception

Role: collaborator

NCT03614494Phase 2Completed

Piroxicam and Levonorgestrel Co-treatment for Emergency Contraception

Role: collaborator

NCT02517463Completed

Ulipristal Emergency Contraception Used Before or After Ovulation

Role: collaborator

NCT02742116Completed

Evaluation of the Implementation of Expanded Carrier Screening Before Pregnancy in Hong Kong

Role: collaborator

NCT01058460Not ApplicableUnknown

HPV-cytology Testing Versus Cytology Testing for the Detection of High Grade CIN

Role: collaborator

All 6 trials loaded